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To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus
on speciﬁc issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11–12
May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in
each of four areas: pathology and molecular biomarkers, ﬁrst-line/second and further lines in advanced disease, early-
stage disease and locally advanced disease. For each question, recommendations were made including reference to the
grade of recommendation and level of evidence. This consensus paper focuses on early-stage disease.
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background to the 2nd ESMO Consensus
Conference on Lung Cancer, Lugano
2013
In 2009, ESMO decided to complement the ESMO Clinical
Practice Guidelines (CPGs) with further recommendations from
‘Consensus Conferences’. For lung cancer, the ﬁrst meeting of
this kind was held in Lugano in 2010, which resulted in the pub-
lication of two consensus manuscripts [1, 2].
The 2nd meeting, held in Lugano in May 2013, followed the
same format as the 1st edition. Four working groups were
appointed, each with 8–10 participants from several disciplines
and led by a chair. A total of 35 experts were involved in this
consensus process (see Panel Members listed in the Appendix).
The four speciﬁc areas were as follows:
NSCLC pathology and molecular biomarkers,
First line, second line and further lines of treatment in
advanced NSCLC,
Early-stage NSCLC (stages I–II),
Locally advanced NSCLC (stage III).
Before the conference, each working group identiﬁed a number
of clinically relevant questions suitable for consensus discussion
and provided the available literature. At the Conference, in paral-
lel sessions, each group discussed and reached agreement on the
questions previously chosen. Decisions were made using studies
published in peer review journals. The consideration of abstracts
was at the discretion of the groups. All relevant scientiﬁc litera-
ture, as identiﬁed by the experts, was considered. A systematic lit-
erature search was not carried out.
The recommendations from each group were then presented
to the full panel of experts and discussed, and a general consen-
sus was reached. The Infectious Diseases Society of America
grading system was used to assign levels of evidence and grades
of recommendation [3].
The consensus ﬁndings of the group on early-stage NSCLC—
approved by the Consensus Conference panel of experts—is
reported here. As there was no prior consensus manuscript in
this domain available, the section on early-stage NSCLC of the
latest CPG [4] was the working basis. Starting from there, 14
questions in nine domain sections were appointed for further
discussion.†See appendix for Panel Members.
*Correspondence to: ESMO Guidelines Working Group, ESMO Head Ofﬁce, Via L. Taddei 4,
CH-6962 Viganello-Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org
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The bulleted recommendations at the end of this paper are
based on the 2013 CPGs, complemented and/or reﬁned by the
consensus process at the Lugano 2013 meeting.
incidence/epidemiology
Question 1a: should experienced multidisciplinary thoracic cancer
centres offer computed tomography (CT) screening outside of a
clinical trial?
Question 1b: can CT screening for subclinical lung cancer be
offered to individual patients asking for it?
None of the four prospective randomised, controlled trials
(RCTs) of lung cancer screening, carried out in the late 1970s
using combinations of chest X-ray and sputum cytology [5–8],
showed a signiﬁcant reduction in lung cancer mortality asso-
ciated with screening.
However, on 4 November 2010, the National Cancer Institute
announced the results of the National Lung cancer Screening
Trial (NLST) which indicated that lung cancer mortality in
speciﬁc high-risk groups could be signiﬁcantly reduced by
annual screening with low-dose computed tomography
(LDCT). The results of the NLST trial documenting this reduc-
tion were published shortly thereafter [9].
Following these ﬁndings, LDCT lung cancer screening in
selected populations was recommended for the ﬁrst time by a
scientiﬁc society [10]. In 2011, the International Association for
the Study of Lung Cancer (IASLC) held a CT screening work-
shop which brought together experts in lung cancer disciplines
from across the globe, to consider standards and quality control
for CT screening. The workshop report [11] suggested, among
other things, that before offering CT screening, quality stan-
dards must be developed, endorsed and embraced in organised
and individualised settings, and that outcome reporting should
be standardised. To reduce the risk of over-diagnosis and over-
treatment, standardised protocols for image interpretation and
nodule management should be developed, and positive cases
should be discussed at multidisciplinary meetings.
To help ensure quality and efﬁcacy control in a screening pro-
gramme, the programme’s clinical, radiological and oncological
data should be archived in a database. The IASLC report also
proposed surgical standards in the screening context, recom-
mending that screening should only be carried out in centres
with access to a full minimally invasive surgical programme;
that the number of resections for benign disease should be low
(<15%); and that for lung cancers <2 cm with pure ground-glass
or part-solid aspect on CT, anatomical segmentectomy with
frozen section analysis of N1 and N2 should be practiced.
The 2013 Lung Cancer Screening Guidelines published by the
American Cancer Society (ACS) [12] restated the ﬁndings of a
2012 systematic review [13], which emphasised that adults
requesting lung cancer screening should enter an organised
screening programme at an institution with expertise in LDCT
screening, and be given access to a multidisciplinary team
skilled in the evaluation, diagnosis and treatment of abnormal
lung lesions. If these criteria are not met, the risks of cancer
screening were considered to be substantial. The review also
recommended that physicians should initiate a thorough discus-
sion of the beneﬁts, limitations and risks of LDCT screening
with those requesting it, should inform current smokers that
they continue to be at risk of developing lung cancer and should
encourage them to enter smoking cessation programmes.
Lung cancer risk models are being developed and tested for
their ability to identify the best target population for lung cancer
screening and also the best screening interval [14]. Until evi-
dence from such models becomes available, the target popula-
tion and screening interval should be those proposed by the
NLST [9].
should experienced multidisciplinary thoracic
cancer centres offer CT screening outside of a
clinical trial?
• Recommendation: LDCT screening reduces lung cancer mor-
tality [I, A] and can be carried out outside a clinical trial pro-
vided it is offered within a dedicated programme with quality
control at a high-volume centre of thoracic oncology experi-
enced in LDCT screening, where the multidisciplinary man-
agement of suspicious nodules is established. Individuals
offered LDCT screening should also be referred to a smoking
cessation programme.
can CT screening for subclinical lung cancer be
offered to individual patients asking for it?
• Recommendation: LDCT screening should not be offered on
an individual basis, but patients requesting screening should
be referred to a dedicated programme as recommended above.
diagnosis
Question 2: should the malignancy calculation methods used in
LDCT screening be used for the clinical assessment of pul-
monary nodules?
Obtaining a deﬁnitive tissue diagnosis before treatment is desir-
able for patients presenting with early-stage NSCLC. However,
this can be challenging for lesions that are inaccessible by bron-
choscopy, as complications following a transthoracic needle
biopsy are reported in up to 15% in population studies, especially
in the elderly, smokers and those with chronic obstructive pul-
monary disease (COPD) [15]. The pre-test risk of malignancy
can be determined using algorithms which take into account the
relevant medical history, smoking habits and radiologic
characteristics of the lung nodule in question, in order to decide
if additional diagnostic or therapeutic procedures are indicated
[16]. All such algorithms have limitations, which are partly
related to the underlying populations from which they were
derived. More recently, studies evaluating LDCT screening for
lung cancer detection have shown that incorporating the nodule
volume doubling time (VDT) [17] and/or ﬂuorodeoxyglucose–
positron emission tomography (FDG–PET) uptake [18, 19] can
also reduce the number of benign lesions excised.
However, VDT measurements are not routinely carried
out outside clinical trials. Differences may exist between the
CT-screened populations and others presenting with lung
cancer, hence the sole use of existing algorithms, VDT or FDG–
PET in isolation, for the purpose establishing a diagnosis of
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early-stage NSCLC cannot be supported at the present time.
Instead, it is recommended that indeterminate solitary pulmon-
ary nodules (SPNs) should be assessed by expert multidisciplin-
ary tumour boards, who will consider all relevant patient,
epidemiological and procedure-related factors, and apply the
existing guidelines for the assessment of lung nodules, such as
the ones of the Fleischner Society [20], recently expanded to
subsolid nodules [21]. Expert multidisciplinary tumour boards
may be best placed to assess the likelihood of benign disease in
their own populations including, where available, algorithms
that have been validated for the population in question [22].
should the malignancy calculation methods used in
LDCT screening be used for the clinical assessment
of pulmonary nodules?
• Recommendation: No, standard existing guidelines for assess-
ment of SPN must be applied [V, C].
Question 3a: is tissue-based diagnosis needed before surgical
intervention?
In principle, tissue-based diagnosis is crucial to any radical
treatment of lung cancer, and any reasonable attempt at pre-
surgical (i.e. pre-resectional) tissue diagnosis is to be pursued
[16, 23].
In the event of a nodule with increased likelihood of malig-
nancy as per current diagnostic algorithms and/or unsuccessful
or too hazardous preoperative diagnostic procedures [15],
experienced multidisciplinary groups can advise to proceed to
surgery according to the principles of minimal invasiveness.
The location, size and solid component of the nodule will have
to be considered when estimating the likelihood of malignancy
and the most favourable approach for the surgical procedure.
is tissue-based diagnosis needed before surgical
intervention?
• Recommendation: A pre-surgical pathological diagnosis is
recommended. In some patients with clinical stage I/II lesions
this is not feasible, and a high likelihood of malignancy based
on assessment of clinical and imaging ﬁndings in an experi-
enced multidisciplinary group may be sufﬁcient [III, B].
Question 3b: is tissue-based diagnosis needed before stereotactic
ablative radiotherapy?
A signiﬁcant proportion of patients with early-stage NSCLC do
not receive a surgical therapy, mainly due to reasons of co-
morbidity and age [24]. Population studies show that patients
with early-stage NSCLC are less likely to have a pathologically
conﬁrmed diagnosis compared with those with more advanced
stage disease, and that both the elderly and those with co-
morbidities were less likely to have a pathological diagnosis of
lung cancer [25]. Obtaining a tissue diagnosis in unﬁt or border-
line operable patients can be more challenging than doing so in
those who are ﬁt to undergo surgery. For ﬁt patients, the
American College of Chest Physicians (ACCP) guidelines have
recommended surgery without a preoperative diagnosis, when
the likelihood of malignancy exceeds 65% [26].
A number of arguments have been used to support the use of
stereotactic ablative radiotherapy (SABR) in inoperable patients
without tissue conﬁrmation of their tumour, but following as-
sessment by an expert multidisciplinary team. Population data
also support the view that failure to establish a pathological
diagnosis reﬂects extensive comorbidity, as such patients have
poorer survival outcomes following SABR [24]. Reassuringly, in
populations where a ﬁnal diagnosis of benign disease is made in
only 6% or less of resected tumours [27], the patterns of local
control and disease recurrence were similar in SABR patients
cohorts either with or without a preoperative diagnosis [28].
Although the ACCP guidelines have recommended a 65% pre-
test likelihood of malignancy before proceeding to ‘non-surgical
biopsy and/or surgical resection unless speciﬁcally contraindi-
cated’, an 85% likelihood of malignancy has been suggested
before proceeding with SABR without pathological diagnosis
[29]. The latter is consistent with the recommendations of the
IASLC that in centres performing CT screening, a ﬁnal patho-
logical diagnosis of benign disease should not exceed 15% [11].
is tissue-based diagnosis needed before
stereotactic ablative radiotherapy?
• Recommendation: An attempt should generally be made to
obtain a pathological diagnosis before SABR. In the event that
tissue sampling is considered excessively hazardous, there
should be at least an 85% chance of malignancy, based upon
accepted criteria [III, A].
staging and risk assessment
Question 4a: what is high risk for surgery? what is the role of
validated risk models?
Risk is a continuous outcome usually expressed as a probability
from 0% to 100%; therefore, what constitutes ‘high’ is arbitrary.
In a clinical setting, patients are the most appropriate persons to
deﬁne what is ‘high’ as relative value depends on personal
(usually unexplained or unquantiﬁable) beliefs. With regard to a
clinical trial or guidelines the value used to deﬁne ‘high’ should
simply be stated.
Risk needs to relate to meaningful speciﬁc outcomes. While a
simple principle, respiratory literature (especially on exercise
testing) is littered with studies that use combined outcomes with
several end points (e.g. death, pneumonia and arrhythmia),
which complicates interpretation [30]. The CALGB 9238 trial
was a prospective multicentre study to validate the use of
primary exercise VO2 measurement for the prediction of surgi-
cal risk [31]. Patients with a peak exercise VO2 <65% of pre-
dicted or <16 ml/kg/min were indeed more likely to suffer
complications (P = 0.0001), and poor outcome (respiratory
failure or death, P = 0.0356). The author’s conclusion was that
their data provided a multicentre validation for the use of exer-
cise VO2 for preoperative assessment of lung cancer patients,
but that an aggressive approach may be warranted in some
patients, as 58 patients who did not meet the algorithm for oper-
ability were resected. They had a 2% mortality rate and a sur-
vival twice as long compared with non-surgical patients.
So, while cardiopulmonary exercise testing is used to screen
for patients ‘at risk’, additional discussion in a multidisciplinary
tumour board and with the patient is needed.
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The risk of in-hospital death can, for example, be estimated
using a validated scoring method such as the Thoracoscore [32].
Each risk model should indeed be validated, an example is the
Goldman cardiac risk index recommended by the American
College of Cardiology/American Heart Association (ACC/
AHA), that was recalibrated for lung resection cohorts [33], and
validated in the latter setting [34].
what is high risk for surgery? what is the role of
validated risk models?
• Recommendation: Validated risk-speciﬁc models can be used
to estimate postoperative mortality and morbidity [III, B].
Question 4b: what is optimal functional cardiopulmonary
evaluation before resection?
When discussing surgical resection for lung cancer, not only
technical resectability should be considered, but also the func-
tional operability, in particular cardiac and pulmonary.
To evaluate cardiac risk, use of the revised cardiac risk index
(RCRI) is recommended—this has recently been modiﬁed into
the so-called recalibrated thoracic RCRI (Table 1, Figure 1) [33].
To calculate this index, four weighted factors are used, and
patients are grouped into four classes with increasing risk. This
index has recently been externally validated [34].
A collaborative task force of the European Respiratory Society
(ERS) and European Society of Thoracic Surgeons (ESTS) estab-
lished clinical guidelines on ﬁtness for radical therapy in lung
cancer patients (surgery and chemoradiotherapy) [35]. In case
FEV1 or DLCO are <80%, exercise testing and split lung function
Table 1. Recalibrated thoracic revised cardiac risk index (adapted
from [33] with permission from Elsevier)
Weighted factors
Ischaemic heart disease 1.5 points
History of cerebrovascular disease 1.5 points
Serum creatinine >2 mg/dl 1 point
Pneumonectomy planned 1.5 points
Class groupings
A 0 points
B 1–1.5 points
C 2–2.5 points
D >2.5 points
Deﬁnitions: Ischaemic heart disease: history of myocardial infarction,
history of positive exercise test, current complaint of chest pain
(myocardial ischaemia), nitrate therapy, ECG with pathologic Q
waves; Cerebrovascular disease: transient ischaemic attack, stroke.
RCRI>2 or:
1) Any cardiac condition
requiring medications
2) A newly suspected cardiac
condition
3) Inability to climb two flights
of stairs
RCRI [2]
High risk surgery (including
lobectomy or pneumonectomy)
Ischaemic heart disease (prior
myocardial infarction, angina
pectoris)
Heart failure
Insulin-dependent diabetes
Previous stroke or TIA
Creatinine ≥2 mg-dL–1
History
Physical examination
Baseline ECG
Calculate RCRI
Need for coronary
intervention
(CABG or PCI)
Cardiac consultation with noninvasive
cardiac testing treatments as per
AHA/ACC guidelines
Postpone surgery
for ≥6 weeks
Lung function tests
(fig. 2)
Continue with ongoing cardiac care
Institute any needed new medical
interventions (i.e. beta-blockers,
anticoagulants or statins)
Yes No
Figure 1. Preoperative cardiac evaluation (reprint from [35], with permission from the European Respiratory Society).
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are recommended to determine the maximum extent of resection
(Figure 2). For sub-lobar resection (wide wedge resection or ana-
tomical segmentectomy), no precise functional criteria are avail-
able. A volume reduction effect may also be taken into account,
especially in patients with heterogeneous emphysema [36, 37].
what is optimal functional cardiopulmonary
evaluation before resection?
• Recommendations: Before considering surgical resection
precise assessment of cardiac and pulmonary function is ne-
cessary to estimate risk of operative morbidity [III, A]. For
cardiac assessment, use of the recalibrated thoracic RCRI is
recommended [III, A]. For functional respiratory assessment
FEV1 and DLCO are required; in case either one is <80%, use
of exercise testing and split lung function are recommended.
In these patients, VO2max can be used to measure exercise cap-
acity and predict postoperative complications [III, A].
treatment of early stages I and II
Question 5a: For which patients is limited (sub-lobar) resection
an acceptable choice?
Although lobectomy is still considered standard therapy for early-
stage T1N0 lung cancer, anatomical segmentectomy or wide
wedge resection are currently reconsidered for small, non-invasive
or minimally invasive lesions, especially those with ground-glass
opacity (GGO) characteristics [38–40]. Two recent reviews [41,
42] and one meta-analysis [43] concluded that well selected use of
sub-lobar resection, especially for pure adenocarcinoma in situ
≤2 cm, yielded similar survival and recurrence rates as lobectomy.
Deﬁnitive recommendations can only be made when the results
of large randomised trials become available.
In some speciﬁc subsets of early-stage adenocarcinoma, sys-
tematic lymph node dissection may not always be required [44].
Recent analysis of the Italian COSMOS screening study showed
that systematic nodal dissection can be avoided in early-stage,
clinically N0 lung cancer when the maximum standardised
uptake value on PET scanning is <2.0 and the pathological
nodule size is ≤10 mm [45].
A lung volume reduction effect may be observed in patients
with heterogeneous emphysema operated for a concurrent
lung cancer located in a diseased part of the lung. A ‘COPD
index’ has been described for better patient selection in this
situation [46]. Several therapeutic surgical options are avail-
able and a speciﬁc algorithm has been developed (Figure 3)
[36, 37].
Cardiac assessment:
low risk or
treated patient
(fig. 1)
FEV1
DL, CO
Both
>80%
Both >30%
Split function
ppo-FEV1
ppo-DL,CO
Either one <80%
At least one <30%
ppo-peak VO2
Exercise testing
Peak VO2
<35% or
<10 mL·kg–1·min–1
<35% or
<10 mL·kg–1·min–1
>35% or
>10 mL·kg–1·min–1
Resection up to
calculated extent
Resection
up to
pneumonectomy
Lobectomy or
pneumonectomy
are usually
not recommended.
Consider other options
>75% or
>20 mL·kg–1·min–1
35–75% or
10–20 mL·kg–1·min–1
Figure 2. Preoperative respiratory evaluation (reprint from [35], with permission from the European Respiratory Society).
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for which patients is limited (sub-lobar) resection an
acceptable choice?
• Recommendations: Sub-lobar resection is generally consid-
ered acceptable for pure GGO lesions or adenocarcinoma
in situ or with minimal invasion [III, B]. Lobectomy is still
considered the standard surgical treatment of tumours ≤2 cm
in size that have a solid appearance on CT [II, B]. In patients
with emphysema and limited pulmonary function, a lung
volume reduction effect may be observed by resecting the lung
cancer and emphysematous lung parts [III, B].
Question 5b: When is open versus video-assisted thoracic
surgery (VATS) versus robotic surgery is preferred for early-
stage NSCLC?
A summary of the literature up to 2012 has been reported in
a meta-analysis of 21 comparative studies, two randomized
and 19 non-randomized [47]. The results suggest that either
form of access yielded similar results with no differences in
in-hospital pulmonary outcomes or mortality. The authors
highlighted reduced systemic recurrence (i.e. improved
disease-free survival, DFS) in patients who underwent
minimal access (video-(VATS)) lobectomy. However, since
the majority of studies were non-randomised, improved DFS
may be due to case selection bias. An update published in
2012 reported lower in-hospital morbidity and shorter length
of hospital stay in patients who underwent VATS lobectomy
[48].
There are no randomised trials comparing robotic surgery
with either open or VATS surgery. A number of case series have
been reporting good outcomes with robotic surgery [49–51].
One study reported similar case–controlled outcomes with
robotic and VATS lobectomy [52].
Clinincal Stage I
Lung Cancer
Reduced lung
function?
(FEV1 < 65%)
No
No
Consider Restrictive
Pathology with higher
associated risks (ILD, IPF)
Severely Impaired
Lung Function?
(FEV1 <30%)
Moderately Impaired Lung
Function?
(FEV1 30–65%)
Ideal LVRS
Candidate
Resection of mass
with concomitant
LVRS
Calculate COPD Index
Predict postop FEV1
Consider sublobar
resection
Consider non-surgical
modalities
(SBRT, RFA)
Consider anatomy of
emphysema, location of
mass, LVRS candidacy
Non-Ideal LVRS
Candidate
Lobectomy with
confidence
Evidence of
Emphysema?
(based on TLC, RV, FEV1/FVC, CT
w/ hyperexpansion, etc)
Yes
Yes
Figure 3. Algorithm for patients with clinical stage I lung cancer and limited pulmonary function due to emphysema (reprinted from [37], with permission
from Elsevier).
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In summary, high-level randomised evidence comparing
VATS to open surgery is sparse. There is no high-quality evi-
dence reporting comparative outcomes between robotic versus
either VATS or open surgery. The majority of case–control
studies conducted to date have been small with limited external
validity (the vast majority were single institution).
when is open versus VATS versus robotic surgery
preferred for early-stage NSCLC?
• Recommendation: Either open or VATS access can be utilised
as appropriate to the expertise of the surgeon [II, A].
Question 6: what is the optimal management of multifocal lung
cancer?
Surgical data regarding the management of multifocal lung
cancer mainly come from retrospective analyses. Bearing this in
mind, current evidence supports surgery as up-front approach
for patients with synchronous nodules in multiple lobes, either
ipsilateral or contralateral. Recent studies of patients undergoing
resection of multiple nodules—two synchronous tumours in
most cases—and without evidence of lymph node involvement
have demonstrated 5-year survival rates >50% [53–55].
However, 5-year survival decreases with the extent of lymph-
nodal involvement [55, 56], and patients with multifocal lung
cancer and documented N2 disease are generally excluded from
complete resection because of poor prognosis following surgery
[55–57]. Besides nodal involvement, in a recent pooled analysis
based on individual patient data of 467 individuals undergoing
resection of multifocal lung cancer in multiple lobes, the follow-
ing poor prognostic factors for survival have been identiﬁed:
advanced age, male gender and unilateral tumour location [55].
The fact that bilateral cancers seem to have a more favourable
prognosis may simply reﬂect the fact that these patients are
more likely to be those with true multiple cancers, and beneﬁ-
tting most from surgery because of non-metastatic disease.
When judging on surgical resectability the aforementioned
prognostic factors should be taken into account.
No consensus exists on the optimal type of surgery for
patients with multifocal lung cancer, although lobectomy for the
main tumour plus sub-lobar resection of the smaller nodule(s)
seems a reasonable approach.
If surgery is not feasible, other approaches such as local abla-
tive (SABR) and/or systemic therapy should be considered,
though scientiﬁc data on this are lacking. Therefore, especially
in the latter case scenario, all treatment decisions should be
taken within the context of a multidisciplinary tumour board.
what is the optimal management
of multifocal lung cancer?
• Recommendation: Complete resection is recommended
whenever possible. If not, additional alternative approaches
such as local ablative (e.g. SABR) and/or systemic treatment
should be discussed within the context of a multidisciplinary
tumour board [III, B].
Question 7: should factors, other than stage, guide the choice of
adjuvant therapy?
Adjuvant chemotherapy is recommended in stage II and III and
should be cisplatin based [58]. The most frequently studied
regimen is cisplatin–vinorelbine [59, 60].
The indication should be further discussed in a multidiscip-
linary tumour board and should consider host factors such as
age, comorbidities, performance status (PS), as well as time
since surgery and pathology report [V, A].
According to data reported from clinical trials, age per se is
not a factor of selection [II, A] [61, 62].
Patients with severe comorbidity were excluded from clinical
trials. In the Ontario Cancer Registry, a detrimental effect from
adjuvant chemotherapy was seen in patients with greater co-
morbidity (Charlson score 3+) but still ﬁt for chemotherapy
[III, C] [63].
Evidence of beneﬁt from adjuvant chemotherapy has been
established in patients PS 0, 1 rarely PS 2 [I, A].
The precise interval limits to start adjuvant chemotherapy
have not been properly addressed in clinical trials. Some trials
(IALT) restricted inclusion to patients resected within 60 days
before randomisation. The Ontario Registry of Canada looked
more carefully at timing and concluded that no difference
was observed between 2 cohorts (0–10 versus 11–16 weeks) [III,
C] [63].
In case of R1 resection (positive resection margin, chest wall),
postoperative radiotherapy should be considered [III, B]. Even if
such patients were not included in the RCTs, adjuvant chemo-
therapy is advised for R1 resection regardless of nodal status
[V, A]. In case chemotherapy and radiotherapy are both admi-
nistered, radiotherapy should be administered after chemother-
apy [V, C].
Adding chemotherapy after radiotherapy for patients with
stage II-N1 disease may be considered [V, C]. Although this was
not properly assessed in clinical studies, there may be a similar
beneﬁt as for resected patients with stage II-N1 disease.
should factors, other than stage, guide the choice
of adjuvant therapy?
• Recommendation: Pre-existing comorbidity, performance
status and time since surgery should be taken into account in
this decision taken in a multidisciplinary tumour board [V, A].
• In the current state of knowledge, the choice of adjuvant
therapy should not be guided by molecular analyses such as,
e.g. ERCC1 or mutation testing [IV, B].
Question 8: what are the indications for salvage surgery after SABR?
The outcome of SABR has been extensively documented in
the literature [64]. Conversely, salvage surgery after SABR has
been reported sporadically [65, 66]. In a recent Japanese series,
post-SABR occurrence local failure or new primary lung was
common (∼40% after 3 years), and about half of these patients
had salvage therapy [67]. The current—very limited—experience
seems to support the feasibility of surgery after SABR [68]. In
one series, however, up to 25% of the patients subjected to SABR
initially refused surgery [69].
In some cases, surgery after SABR is carried out for complica-
tions related to SABR [70]. Acute complications of SABR, such
as skin irritation, fatigue or cough occur in in 5%–40% of the
patients and usually are transient [71]. Less common are late
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complications such as radiation pneumonitis, chest wall pain or
rib fracture, haemoptysis or bronchial stenosis or necrosis.
Therefore, along with pre-existing comorbidities, chest wall
morbidity and pulmonary toxicity after SABR need to be care-
fully factored into the decision-making process for secondary
surgery [69, 70]. Irrespective of whether post-SABR surgery is
done in an elective or in an emergency setting, histological diag-
nosis of lung cancer will be crucial for subsequent treatment.
what are the indications for salvage surgery after
SABR?
• Recommendation: Salvage surgery, if feasible, may be offered
to patients having complications after SABR [V, B]. Salvage
surgery may be offered, if feasible, using the same indications
as for primary surgery in progressive disease after SABR,
albeit surgery in these patients may be more difﬁcult due to
higher operative risk [V, B].
follow-up
Question 9a: what is the optimal follow-up after surgery for
early-stage NSCLC?
The incidence of lung cancer at primary screening of high-risk
patients with LDCT is as low as 1% per patient per year, but
this approach has been proven to reduce lung cancer deaths [9].
A signiﬁcant proportion (20%–40%) of patients who underwent
a complete resection for pathological stage IA–IIB NSCLC
develop a locoregional or distant recurrence [59, 72]. These
patients have a constant hazard rate for disease recurrence of
6%–7% per patient per year during the ﬁrst 4 years, diminishing
to 2% per patient per year thereafter [72]. In addition, they have
a smooth increase of the hazard rate for second primary cancer
from 1% to 3% per patient per year during the ﬁrst 3 years,
which does not diminish over time [73, 74].
Event dynamics studied in 1506 resected NSCLC patients
demonstrated distinct recurrence peaks occurring at around
9 months, and at the end of the second and fourth year [74].
Based on these results, a surveillance strategy can be recom-
mended for patients who underwent a curative resection for
stage I–II NSCLC, despite the absence of a well-designed rando-
mised, controlled trial addressing the effect on survival out-
comes with this strategy.
The ESMO 2013 CPGs recommended follow-up visits every
3–6 months during 2–3 years, less often (e.g. annually) there-
after, with history and physical examination, chest X-ray and
annual CT as appropriate tools [III, B]. Based on the above-
mentioned data, surveillance every 6 months for 2–3 years with
a contrast-enhanced spiral CT at 12 and 24 months, and there-
after an annual visit including chest CT in order to detect
second primary tumours can be advised.
Despite several reports on a better sensitivity of PET-CT to
detect disease recurrence in asymptomatic patients, compared
with spiral chest CT scan alone, this is not recommended
because no survival beneﬁt has been demonstrated [II, D]. PET-
CT can be helpful for the work-up of a suspected lung cancer
lesion detected at CT surveillance [75].
what is the optimal follow-up after surgery for early-
stage NSCLC?
• Recommendation: Surveillance every 6 months for 2–3 years
with a visit including history, physical examination and—
preferably contrast enhanced—spiral chest CT at 12 and 24
months is recommended, and thereafter an annual visit in-
cluding history, physical examination and chest CT in order
to detect second primary tumours [III, B]. Follow-up PET-CT
is not recommended [II, D].
Question 9b: what is the optimal follow-up after SABR for early-
stage NSCLC?
Considering that SABR is still a relatively new technique in Europe,
close follow-up after treatment is important. The frequency of the
follow-up visits and imaging should be tailored to the individual
centre according to experience and also to the individual patient,
taking into account suitability for salvage treatment.
The incidence of early and late radiation-induced lung changes
on chest CT ranges from 54%–79% to 80%–100%, respectively
[76]. The late changes can mimic the appearance of recurrent
disease, but only a small proportion of patients will have local re-
currence conﬁrmed by biopsy or further imaging [77, 78].
The clinical utility of surveillance with FDG–PET-CT after
SABR at pre-deﬁned time points has not been clearly deﬁned
[76, 77]. PET-CT is generally carried out when recurrence after
SABR is suspected based on serial spiral chest CT. However,
PET should be interpreted with caution as moderate hyper-
metabolic activity may persist for up to 2 years following treat-
ment without deﬁnite evidence of recurrence [79]. Optimal
SUV max thresholds that correlate with a high risk of recurrence
are still to be deﬁned, as evidence is very limited, due to the
low incidence of local recurrences in the available literature.
A growing body of evidence, mainly from retrospective studies,
suggests that SUV max above 5 at 6 months or more from SABR
is associated with a high risk of local recurrence [76, 80–82].
However, due to false-positive ﬁndings on PET, patients suitable
for salvage treatment should undergo a biopsy.
what is the optimal follow-up after SABR for early-
stage NSCLC?
• Recommendations: In centres where SABR was recently
implemented, we recommend follow-up of patients as per
ESMO CPG 2013 plus 6 monthly CT scans for 3 years to
benchmark treatment-related acute/late side-effects and local
control against the available literature [III, B]. For individual
patients, follow-up as per ESMO CPG 2013 and 6 monthly
CT for 3 years are recommended for patients who are suitable
for salvage treatment (e.g. surgery, local ablative therapy)
[III, B]. The frequency of the follow-up visits can be tailored
to the individual patient for those not suitable for salvage
treatment [V, B]. The clinical utility of surveillance with
FDG–PET during follow-up after SABR at pre-deﬁned time
points has not been clearly deﬁned and is not recommended
[III, D]. The selective use of FDG–PET is recommended when
recurrence after SABR is suspected based on serial spiral chest
CT [III, B]. Due to a high number of false-positive ﬁndings on
FDG–PET, patients suitable for salvage therapy should
undergo a biopsy, whenever possible [III, B].
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Table 2. Summary of recommendations
Incidence/Epidemiology
• Screening with low-dose CT reduces lung cancer-related mortality [I, A]. It is not yet ready for large-scale implementation, because of unanswered
questions regarding deﬁnition of at-risk population, timing, interval and method of CT (especially 2D versus 3D evaluation), how to handle (false-)
positive ﬁndings and especially cost-effectiveness in relation to smoking cessation.
• LDCT screening can be carried out outside a clinical trial provided it is offered within a dedicated programme with quality control, in a centre with
experience in CT screening, a large volume of thoracic oncology activity and multidisciplinary management of suspicious ﬁndings [I, B].
Candidates are current or former heavy smokers (≥30 pack-years or ≤15 years since smoking cessation) aged 55–74 years, who are well informed
about potential beneﬁt and risks. Individuals offered LDCT screening should be referred to a smoking cessation programme.
• LDCT screening should not be offered on an individual basis, but patients requesting screening should be referred to a dedicated programme as
recommended above [V, B].
• Other screening methods, such as chest X-ray, sputum analysis or biomarkers are not recommended for clinical use [I, C].
Diagnosis
• Bronchoscopy is the recommended test to obtain a pathological diagnosis of centrally located tumours [III, A].
• The diagnostic approach to non-calciﬁed pulmonary nodules should be based on existing standard guidelines [III, A]. Likelihood of malignancy
calculation methods used in CT screening studies should not yet be used for the clinical assessment of pulmonary nodules [V, C].
• A pre-treatment pathological diagnosis is recommended. In some patients with clinical stage I/II lesions, this is not feasible, and a high likelihood
of malignancy based on assessment of clinical and imaging ﬁndings in an experienced multidisciplinary group may be sufﬁcient [III, B].
• A pre-treatment pathological diagnosis is strongly recommended for all patients before SABR, unless a multidisciplinary tumour board is of the
opinion that the risk-beneﬁt ratio of the procedure is unacceptable [III, B].
• An attempt should generally be made to obtain a pathological diagnosis before SABR. In the event that tissue sampling is considered excessively
hazardous, there should be at least an 85% chance of malignancy, based upon accepted criteria [IIIA].
Staging and risk assessment
• In non-metastatic NSCLC, detailed locoregional staging according to the 7th TNM staging system [83] and cardiopulmonary ﬁtness of the patient
determine the choice of treatment [III, A].
• For patients with a non-centrally located resectable tumour and absence of nodal metastasis on both CT and PET images, surgical resection is
recommended [I, A].
• For patients with suspect mediastinal lymph node metastasis on CT or PET images (unless bulky) pathological conﬁrmation of nodal disease is
recommended [I, A].
• The preferred ﬁrst technique for pathological conﬁrmation of suspect nodes is needle aspiration under endobronchial ultrasound and/or endoscopic
ultrasound guidance. Mediastinoscopy is the test with the highest negative predictive value to rule out mediastinal lymph node disease [I, A].
• The risk of postoperative morbidity and mortality can be estimated using validated risk-speciﬁc models [III, B].
• Before considering surgical resection, precise assessment of cardiac and pulmonary function is necessary to estimate risk of operative morbidity
[III, A].
• For cardiac assessment, use of the recalibrated thoracic revised cardiac risk index (RCRI) is recommended [III, A].
• Formal lung function testing should be undertaken to estimate postoperative lung function. For patients with FEV1 and DLCO >80% in their
pulmonary function tests and no other major comorbidities, surgical resection is recommended [III, A]. For others, exercise testing and split lung
function are recommended. In these patients, VO2max can be used to measure exercise capacity and predict postoperative complications [III, A].
• Comorbidities should be evaluated and optimised before surgery [III, A].
Treatment of early stages I and II
• Surgery should be offered to patients with stage I and II NSCLC who are willing to accept procedure-related risks [III, A].
• Anatomical resection (lobectomy) is preferred over lesser resections such as wedge or segment resection [I, A].
• Sub-lobar resection is generally considered acceptable for pure GGO lesions or adenocarcinomas in situ or with minimal invasion [III, B].
Lobectomy is still considered the standard surgical treatment of tumours ≤2 cm in size that have a solid appearance on CT [II, B].
• In patients with emphysema and limited pulmonary function, a lung volume reduction effect may be observed by resecting the lung cancer and
emphysematous lung parts [III, B].
• Lymph node dissection should conform to IASLC speciﬁcations for staging [III, A].
• Either open thoracotomy or VATS access can be utilised as appropriate to the expertise of the surgeon [III, A].
• For patients with multifocal lung cancer, complete resection is recommended whenever possible. If not, additional alternative approaches such as
local ablative (e.g. SABR) and/or systemic treatment should be discussed within the context of a multidisciplinary tumour board [III, B].
• Adjuvant chemotherapy should be offered to patients with resected stage II and III NSCLC [I, A] and can be considered in patients with resected
stage IB disease and a primary tumour >4 cm [II, B]. Pre-existing comorbidity, time from surgery and postoperative recovery need to be taken into
account in this decision taken in a multidisciplinary tumour board [V, A].
• For adjuvant chemotherapy, a two-drug combination with cisplatin is preferable [I, A]. In randomised studies, the attempted cumulative cisplatin
dose was up to 300 mg/m², delivered in three to four cycles. The most frequently studied regimen is cisplatin–vinorelbine.
• In the current state of knowledge, the choice of adjuvant therapy should not be guided by molecular analyses such as, e.g. ERCC1 or mutation
testing [IV, B].
Continued
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Table 2. Continued
• In the current state of knowledge, targeted agents should not be used in the adjuvant setting [II, A].
• In view of the equivalence of neo-adjuvant and adjuvant chemotherapy for overall survival, the consistent results and broad evidence base support
adjuvant chemotherapy as the timing of choice [I, A].
• The non-surgical treatment of choice for stage I NSCLC is stereotactic ablative radiotherapy (SABR). The dose should be to a biologically
equivalent tumour dose of ≥100 Gy, prescribed to the encompassing isodose [III, A].
• SABR for early-stage peripheral lung tumours is associated with low toxicity in patients with COPD and the elderly [III, A].
• Salvage surgery, if feasible, may be offered to patients having complications post-SABR [V, B].
• Salvage surgery, if feasible, may be offered, using the same indications as for primary surgery in progressive disease after SABR, but surgery may be
more difﬁcult with higher operative risk [V, B].
• For medically inoperable patients with tumours with a size >5 cm and/or central location, radical radiotherapy using more conventional or
accelerated schedules is recommended [III, A].
• Postoperative radiotherapy in completely resected early-stage NSCLC is not recommended [I, A].
• In case of R1 resection (positive resection margin, chest wall), postoperative radiotherapy should be considered [IV, B].
• Even if such patients were not included in RCTs, adjuvant chemotherapy should be given to R1 resection regardless of nodal status [V, A].
• In case chemotherapy and radiotherapy are administered, radiotherapy should be administered after chemotherapy [V, C].
Follow-up
• NSCLC patients treated with radical intent should be followed for treatment-related complications, detection of treatable relapse or occurrence of
second primary lung cancer [III, A].
• Surveillance every 6 months for 2–3 years with a visit including history, physical examination and—preferably contrast enhanced—spiral chest CT
at 12 and 24 months is recommended, and thereafter an annual visit including history, physical examination and chest CT in order to detect
second primary tumours [III, B].
• Follow-up PET-CT is not recommended [II, D].
• In centres where SABR was recently implemented, we recommend follow-up of patients as per ESMO CPG 2013 plus 6 monthly CT scans for 3
years to benchmark treatment-related acute/late side-effects and local control against the available literature [III, B].
• For individual patients, follow-up as per ESMO CPG 2013 and 6 monthly CT for 3 years are recommended for patients who are suitable for
salvage treatment (e.g. surgery, local ablative therapy) [III, B]. The frequency of the follow-up visits can be tailored to the individual patient for
those not suitable for salvage treatment [V, B].
• The clinical utility of surveillance with FDG–PET during FU after SABR at pre-deﬁned time points has not been clearly deﬁned and is not
recommended [III, D].
• The selective use of FDG–PET is recommended when recurrence after SABR is suspected based on serial spiral chest CT [III, B].
• Due to a high number of false-positive ﬁndings on PET, patients suitable for salvage therapy should undergo a biopsy, whenever possible [III, B].
• NSCLC patients should be offered smoking cessation, as this leads to superior treatment outcomes. Combining behaviour techniques with
pharmacotherapy is the preferred approach [I, A].
Table 3. Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America-United States Public Health
Service Grading Systema)
Levels of evidence
I Evidence from at least one large randomized, controlled trial of good methodological quality (low potential for bias) or meta-analyses of
well-conducted randomized trials without heterogeneity
II Small randomized trials or large randomized trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials
or of trials with demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–control studies
V Studies without control group, case reports, experts opinions
Grades of recommendation
A Strong evidence for efﬁcacy with a substantial clinical beneﬁt, strongly recommended
B Strong or moderate evidence for efﬁcacy but with a limited clinical beneﬁt, generally recommended
C Insufﬁcient evidence for efﬁcacy or beneﬁt does not outweigh the risk or the disadvantages (adverse events, costs,…), optional
D Moderate evidence against efﬁcacy or for adverse outcome, generally not recommended
E Strong evidence against efﬁcacy or for adverse outcome, never recommended
aFrom [3] with permission from the Infectious Diseases Society of America.
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note
A summary of recommendations is provided in Table 2. Levels
of evidence and grades of recommendation have been applied
using the system shown in Table 3. Statements without grading
were considered justiﬁed standard clinical practice by the
experts and the ESMO faculty.
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